Correction to: Low-dose aspirin for the prevention of severe preeclampsia in patients with chronic kidney disease: a retrospective study

Objective The objective of the study was to investigate the effects of low-dose aspirin (LDA) during pregnancy on the prevention of preeclampsia in patients with chronic kidney disease (CKD). Methods The clinical data of pregnant women with CKD were retrospectively analyzed at Peking University First Hospital between January 2013 and January 2020. Among 287 pregnant women with stage 1–2 CKD, 63 patients who were treated with LDA were included in study group 1, and 63 patients who were not treated with aspirin were allocated to control group 1. Among 41 pregnant women with stage 3–5 CKD, 22 patients who were treated with LDA were included in study group 2, and 19 patients were allocated to control group 2. Pregnancy outcomes of the patients with stage 1–2 and stage 3–5 CKD who received LDA during pregnancy and those who did not were compared. Results No significant difference was observed in the incidence of preeclampsia or severe preeclampsia between study and control group 1. The patients in study group 2 had a lower incidence of severe preeclampsia than those in control group 2 (3/22 [13.6%] vs. 8/19 [42.1%], P = 0.04). Among the patients with stage 3–5 CKD, LDA therapy during pregnancy was associated with a lower risk of severe preeclampsia (odds ratio = 0.22, 95% confidence interval: 0.074–0.993; P = 0.049). Conclusions LDA therapy during pregnancy can reduce the risk of severe preeclampsia in patients with stage 3–5 CKD. Prospective studies are needed to further explore the preventive effects of aspirin on preeclampsia in patients with stage 1–2 CKD. Graphic abstract